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Abstract
Since the ﬁrst carbapenem-resistant Klebsiella pneumoniae strain
was isolated in 2008, Enterobacteriaceae with reduced suscepti-
bility to one or more carbapenems have emerged sporadically
in different geographical regions in Croatia. These observations
gave rise to a multicenter study on carbapenem resistance in
Enterobacteriaceae from Croatia. Fifty-seven carbapenem-non-
susceptible strains of Enterobacteriaceae were collected during
2011–2012 from four large hospital centres in Croatia. Overall,
36 strains produced VIM-1 b-lactamase, three produced
NDM-1, and one produced KPC-2. A high degree of clonal
relatedness was observed in Enterobacter cloacae and Citrobacter
freundii strains, in contrast to K. pneumoniae strains. BlaVIM genes
were located within class1 integron which contained genes
encoding resistance to aminoglycosides (aacA4). The study found
strong association between blaVIM and qnrB6 and between
blaNDM and qnrA6 genes.
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Carbapenems are often used to treat infections with Entero-
bacteriaceae expressing extended-spectrum b-lactamase
(ESBL) and AmpC enzymes. However, b-lactamase-mediated
resistance to carbapenems has been reported in Enterobacte-
riaceae, mostly because of expression of class A serin
b-lactamases (KPC, SME, IMI, and NMC), class B metal-
lo-b-lactamases (MBLs) of the IMP, VIM or NDM family, or
OXA-48 b-lactamase belonging to the class D b-lactamase
family. Furthermore, carbapenem resistance can be mediated
by hyperproduction of ESBLs or plasmid-mediated AmpC
b-lactamases combined with porin loss [1]. The ﬁrst carbape-
nem-resistant enterobacteria in Croatia was an NDM-
1-producing Klebsiella pneumoniae strain isolated in 2008 in
the University Hospital Centre Zagreb [2]. Later, in 2011, a
KPC-2-positive K. pneumoniae strain was isolated from the
same institution [3]. A remarkable increase in the number of
carbapenem-resistant isolates was observed in 2012. This
observation gave rise to a multicentre study on carbapenem
resistance in Enterobacteriaceae from Croatia.
A total of 57 carbapenem-non-susceptible strains of Entero-
bacteriaceae (32 Enterobacter cloacae, 13 K. pneumoniae, eight
Citrobacter freundii, one Klebsiella oxytoca, one Escherichia coli,
one Serratia marcescens, and one Enterobacter amnigenus) from
various clinical specimens were collected during 2011–2012
from four large hospital centres located in different geograph-
ical regions of Croatia; the majority were from University
Hospital Centre (UHC) Zagreb (52 strains), Clinical Hospital
Centre Sisters of Mercy Zagreb (one strain), UHC Split (UHC;
three strains), and General Hospital Pula (one strain). The total
numbers of enterobacterial strains in the participating centres
were 11 891 in UHC Zagreb, 3040 in Sisters of Mercy Hospital,
3828 in UHC Split, and 7707 in General Hospital Pula, with 121
(1%) strains, four (0.1%) strains, 28 (0.7%) strains and one
(0.01%) strain with reduced susceptibility to at least one
carbapenem, respectively. The strains with reduced suscepti-
bility to either imipenem, meropenem (zone diameter of
<23 mm) or ertapenem (zone diameter of <22 mm) were
collected from 31 December 2011 until 31 December 2012.
Only the strains fully resistant to at least one carbapenem were
subjected to molecular analysis of resistance mechanisms.
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The total number of microbiology laboratories in Croatia is
39, and four of them participated in this study (the locations of
the centres are shown in the map in Fig. S1). The antimicrobial
susceptibilities to a wide range of antibiotics were determined
with the disk diffusion and broth microdilution method, and
interpreted according to CLSI breakpoints [4]. MICs of
tigecycline were interpreted according to the FDA break-
points for Enterobacteriaceae (susceptible, ≤2 mg/L; intermedi-
ate, 4 mg/L; resistant, ≥8 mg/L). The double-disk synergy test
[5] and CLSI combined disk test with the addition of clavulanic
acid [4] were performed to detect ESBLs. Plasmid-mediated
AmpC b-lactamases were detected with a combined disk test
with cephalosporin disks combined with 3-aminophenylbo-
ronic acid (PBA). The modiﬁed Hodge test was used to screen
for the production of carbapenemases [6]. Additionally, the
strains were tested with combined disk tests with imipenem
and meropenem alone and combined with PBA, 0.1 M EDTA
or both to screen for KPC, MBLs, or simultaneous production
of KPC and MBL, respectively [7].
The strains were uniformly resistant to amoxycillin alone
and combined with clavulanate, piperacillin, cefazoline, ce-
furoxime, cefotaxime, ceftriaxone, ceftazidime, and ertapenem,
but uniformly susceptible to colistin. High resistance rates
were observed for piperacillin–tazobactam (94.7%), merope-
nem (79.0%), imipenem (70%) ciproﬂoxacin (68.4%), gentami-
cin (70.2%), and cefepime (63.2%). Amikacin and tigecycline
maintained good activity, with resistance rates of 14% and 7%,
respectively. Susceptibility to tigecycline was variable, with
MICs ranging from 0.25 to 8 mg/L. Seventeen strains had
negative Hodge test results (seven K. pneumoniae, nine E. clo-
acae, and one Escherichia coli), and all showed resistance to
ertapenem, and variable levels of susceptibility/resistance to
imipenem or meropenem. The double-disk synergy test and
the combined disk test with clavulanic acid were positive in all
but four strains, indicating the production of ESBLs in 53
strains. The results of the modiﬁed Hodge test with carba-
penems were consistent with the activity of carbapenemases in
40 of 57 strains. The combined disk test with PBA gave a
positive result in one strain, as is is typical for KPC, and the
rest of the 39 carbapenemase-positive strains showed
augmentation of inhibition zone with EDTA, indicating the
production of MBLs.
The transferability of meropenem resistance was deter-
mined by conjugation (broth mating method), with Escherichia
coli A15R, which is resistant to rifampicin, and Escherichia coli
J65, which is resistant to sodium azide [8]. Transconjugants
were selected on combined plates containing meropenem
(1 mg/L) to inhibit the growth of the recipient strain, and
rifampicin (256 mg/L) or sodium azide (100 mg/L) to inhibit
the growth of the donor strain.
Fourteen E. cloacae, three C. freundii and four K. pneumoniae
strains transferred carbapenem resistance to the Escherichia
coli recipient. The frequency of conjugation ranged from
1 9 108 to 3 9 104. MICs of carbapenems in transconju-
gants were one to two dilutions lower than those of their
respective donors.
Isoelectrofocusing was performed according to Matthew
et al. [9]. Thirty-six strains (63%) produced a b-lactamase with
a pI of 5.3, corresponding to VIM-1, three produced a
b-lactamase with a pI of 5.8, corresponding to NDM-1 (5%),
and one produced a b-lactamase with a pI of 6.7, correspond-
ing to KPC-2 (1.8%), as shown in Table 1. Forty-eight strains
showed a pI band of 5.4, consistent with TEM-1, 54 showed a
pI band of 8.9, consistent with CTX-M-15, and 45 showed a pI
band of >9, consistent with AmpC b-lactamase. Fourteen
K. pneumoniae strains showed a band with a pI of 7.6,
corresponding to the intrinsic SHV-1 b-lactamase of this
species (Table 1). The presence of genes encoding broad-spec-
trum b-lactamases and ESBLs (blaSHV, blaTEM, blaCTX-M, and
blaPER-1) [10–13], plasmid-mediated AmpC b-lactamases [14],
class A carbapenemases (blaKPC, blaSME, blaIMI, and blaNDM),
MBLs (blaVIM, blaIMP, and blaNDM) and carbapenem-hydrolysing
oxacillinases (blaOXA-48) [15] was determined by PCR with
protocols and conditions as described previously. PCR assays
with primers 50-CS and 30-CS combined with forward and
reverse primers for blaVIM were performed to determine the
location of blaVIM within the class 1 integron [16]. Amplicons
were column-puriﬁed with a Qiagen DNA puriﬁcation kit (Inel,
Zagreb, Croatia), and sequenced directly by Macrogene
Europe sequencing service (sequenced in South Korea).
BlaKPC-2 was carried by only one K. pneumoniae strain. BlaVIM
was carried by 22 E. cloacae strains, seven C. freundii strains,
four K. pneumoniae strains, one K. oxytoca strain, one S. mar-
cescens strain, and one E. amnigenus strain, and was associated
with TEM-1 in 32 strains, CTX-M-15 in 34 strains, CMY in ten
strains, and DHA-1 in one strain. Three strains were found to
produce NDM-1-type MBLs (one E. cloacae strain, one
C. freundii strain, and one K. pneumoniae strain), accompanied
by CTX-M-15 and CMY-4 in all three. Twenty-one transcon-
jugant strains were subjected to PCR with primers speciﬁc for
KPC, VIM and NDM b-lactamases, in order to analyse
carbapenem resistance in an isogenic Escherichia coli strain.
Nineteen strains were found to be positive for blaVIM, one for
blaKPC, and one for blaNDM, like their respective donors. The
strains without true carbapenemases did not transfer carba-
penem resistance to the Escherichia coli recipient strain. BlaVIM
was located within the class 1 integron, which contained genes
encoding resistance to aminoglycosides (aacA4) as the ﬁrst
gene cassette. The plasmid-borne quinolone resistance genes
qnrA, qnrB and qnrS were determined by PCR as described
ª2014 The Authors
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previously [17]. The study found strong associations between
blaVIM and qnrB6 and between blaNDM and qnrA6. The majority
of quinolone-resistant strains were positive for qnr genes
(63%). The remaining 37% probably had mutations in gyrA or
parC, but the clariﬁcation of these resistance mechanisms was
beyond the scope of this study.
Similar ﬁndings were reported previously [18], owing to the
same plasmid location of MBL and qnr determinants.
PCR-based replicon typing (PBRT) according to Carattoli et al.
[19] was applied to type the resistance plasmids carrying
carbapenemase genes. All NDM-positive strains belonged
to PBRT A/C, whereas 26 VIM-positive strains belonged to
PBRT A/C, and eight VIM-positive strains belonged to PBRT L/
M, as shown in Table 1. Pulsed-ﬁeld gel electrophoresis
(PFGE) genotyping of XbaI-digested genomic DNA was
performed with a CHEF-DRIII system (Bio-Rad, Hercules,
CA, USA), as described previously [20]; the images were
processed with Gel-Compar software. A high degree of clonal
relatedness was observed in E. cloacae and C. freundii (Fig. 1b,
c), in contrast to K. pneumoniae, which showed distinct PFGE
patterns (Fig. 1a). Among K. pneumoniae strains, eight clones
were identiﬁed, containing subclones. Nine clones were
detected in E. cloacae, with one dominant clone including 16
strains. C. freundii strains were allocated to three clusters, with
one dominant cluster containing six strains. Two K. pneumo-
niae strains (15 and 29) were also genotyped with multilocus
sequence typing according to Diancourt [21]. One K. pneumo-
niae strain positive for KPC-2 (15) belonged to ST258, and one
(29) belonged to ST36.
The true carbapenemases emerged in signiﬁcant numbers in
Croatia in 2011. Here, the molecular epidemiology and genetic
basis of carbapenem resistance were investigated in a collec-
tion of 57 carbapenem-non-susceptible Enterobacteriaceae
strains obtained in four hospitals located in different geo-
graphical regions. The carbapenemases found in this study
belonged to the KPC, NDM and VIM families.
K. pneumoniae strains with KPC carbapenemases were ﬁrst
detected in North Carolina in 1996; they then spread along the
east coast of the USA, and ﬁnally across the whole country.
Outside of the USA, K. pneumoniae strains producing KPCs
spread widely in Israel, Greece, Poland, Hungary, Austria,
Germany, Switzerland and Italy, and later in most other
European countires [22]. The ﬁrst report of KPC b-lactamases
in Croatia originated from UHC Zagreb in 2011 [3]. This
concerned a single K. pneumoniae strain, and, owing to
effective infection control measures (isolation of patients),
the strain did not spread throughout the hospital. The second
case was a K. pneumoniae strain from Sisters of Mercy Hospital
in 2012, reported in this study. The strain was imported from
another hospital as a result of patient transfer. A KPC-2
b-lactamase with similar properties was previously reported
from Switzerland, Greece, Germany, Belgium, Italy, and Israel
[22].
The majority of our MBL-positive Enterobacteriaceae carried
blaVIM-1. VIM-1 was previously reported in K. pneumoniae and
E. cloacae from Greece, Austria, Italy, Spain, France, Germany,
Turkey [22], and Taiwan [23]. The most frequent type of VIM
MBL found previously in Enterobacter species and Citrobacter
species was VIM-2, reported from Japan, Greece, and Taiwan
[16,22,23], in contrast to our ﬁnding of VIM-1 as a dominant
MBL found in E. cloacae strains. The majority of VIM-positive
strains harboured additional TEM-1 and CTX-M-15 b-lacta-
mases, the genes for which are usually carried on the same
plasmid as blaVIM, whereas only nine were positive for blaCMY.
The strong association between VIM b-lactamases, ESBLs and
plasmid-mediated AmpC b-lactamases was also reported
previously [18].
The NDM-1 MBL was found in this study in three strains.
None of the patients infected with NDM-positive strains had a
history of travel abroad to the countries where this type of
MBL is endemic, such as India and Pakistan. This type of
b-lactamase originated from India [24], but has also been
reported from Canada [25], Austria [26], France, the UK [22],
China [27], Hong Kong [28], and many other countries [29].
The occurrence of NDM and KPC b-lactamases was sporadic
in our study, in contrast to the endemic spread of VIM-1.
The fact that clonally related strains harboured different
types of carbapenemase could be explained by the acquisition of
resistance traits after the clonal spead had occurred. A high
degree of clonal relatedness was observed only in E. cloacae and
C. freundii, in contrast to K. pneumoniae, which showed distinct
PFGE patterns. We found examples of identical PFGE patterns
associated with strains from different units of the same hospital,
suggesting clonal spread of resistant strains. Dissemination of
clonally related VIM-positive E. cloacae strains was associated
with persistent outbreaks in UHC Zagreb, in contrast to other
reports, where K. pneumoniae was dominant [22].
Seventeen strains resistant only to ertapenem and negative
for true carbapenemases but positive only for ESBL should be
further tested for the lack of OmpK35 and OmpK36, to clarify
the exact resistance mechanism. Among those non-carbape-
nemase-producing strains, CTX-M-15 was the dominant type
of ESBL, as in VIM-positive strains. Two E. cloacae strains
positive only for blaCTX-M-15 without blaCARB had similar PFGE
proﬁles as the strains containing blaVIM in combination with
blaCTX-M-15, raising the possibility that blaCTX-M-15-positive
clones acquired blaVIM-1 under the selective pressure of
carbapenems.
The majority of VIM-positive E. cloacae strains belonged to
PBRT L/M or PBRT A/C. PBRT L/M was the dominant plasmid
ª2014 The Authors
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FIG. 1. (a) Pulsed-ﬁeld gel electrophoresis (PFGE)dendrogramofKlebsiella pneumoniae strains (n = 12; one strainwasnot analysed). (b) PFGEdendrogramof
Enterobacter cloacae strains (n = 30; two strains were not analysed). (c) PFGE dendrogram of Citrobacter freundii strains (n = 8). Strains were considered to be
clonally related if they showed>80 similarity in the banding pattern. The imageswere processedwithGel-Compar software, and a dendrogramwas computed
after band intensity correlation by the use of global alignmentwith 2%optimization. ICU, intensive-care unit; IV, intravenous; UHC,UniversityHospital Centre.
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replicon type at the beginning of 2012, but was later replaced
by PBRT A/C.
Most of the MBL strains originated from UHC Zagreb,
which is the largest hospital in Croatia. Haematology and
nephrology wards with bone marrow and kidney
transplantation units were the most important reservoir of
blaMBL. In other hospital centres, the occurrence of carbape-
nemase-producing strains was sporadic, and in most cases they
were imported. The strain from Pula was obtained from the
patient treated previously in Zagreb, and the strain from
Sisters of Mercy Hospital was from a patient who had
previously lived in Germany.
The drawback of the study was that it did not include more
strains from other hospitals, in order to gain a better insight
into the spread of carbapenemase-producing strains in the
whole of Croatia. Nevertheless, it revealed a high prevalence
of VIM-1-producing E. cloacae that was not linked to a single
clone, even though one clone was more commonly identiﬁed
and included 16 strains from the same institution. Prevention
and control measures applied in Croatian hospitals are focused
on general cleaning of the wards and equipment, the screening
of patients upon admission (rectal swab and stool), the
isolation of colonized patients, an emphasis on hygiene
measures, an adequate number of healthcare workers, partic-
ularly in the intensive-care unit, and a restricted, well-deﬁned,
antibiotic prescription policy.
To our knowledge, this is the ﬁrst national surveillance
study on carbapenem-resistant Enterobacteriaceae in Croatia,
and, although the majority of strains originated from one
clinical centre, the study reports the dissemination of carba-
penem-resistant Enterobacteriaceae in different geographical
regions of Croatia, and emphasizes the ability of Enterobacte-
riaceae to cause epidemic/endemic outbreaks and also to
acquire various resistance genes circulating in the hospital
environment.
Transparency Declaration
The authors report no conﬂicts of interest.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Participating centers were: UHC-Zagreb,
Sisters of Mercy Hospital Zagreb, General Hospital Pula,
UHC- Split.
References
1. Queenan AM, Bush K. Carbapenemases: the versatile b-lactamases. Clin
Microbiol Rev 2007; 20: 440–458.
2. Mazzariol A, Bosnjak Z, Ballarini P et al. NDM-1 producing Klebsiella
pneumoniae, Croatia. Emerg Infect Dis 2012; 18: 532–534.
3. Bedenic B, Mazzariol A, Plecko V et al. First report of KPC-pro-
ducing Klebsiella pneumoniae in Croatia. J Chemother 2012; 24:
237–239.
4. Clinical and Laboratory Standards Institute. Performance standards for
antimicrobial susceptibility testing; 22th informational supplement.
Approved standard M100-S22. Wayne, PA: CLSI, 2012.
5. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spec-
trum b-lactamases conferring transferable resistance to newer b-lac-
tam agents in Enterobacteriaceae: hospital prevalence and susceptibility
patterns. Rev Infect Dis 1988; 10: 867–878.
6. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test
and the imipenem-EDTA-double-disk synergy test for differentiating
metallo-b-lactamase-producing isolates of Pseudomonas spp. and Aci-
netobacter spp. J Clin Microbiol 2003; 41: 4623–4629.
7. Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A. A sensitive
screening test for suspected class A carbapenemase production in
species of Enterobacteriaceae. J Clin Microbiol 2009; 47: 1631–1639.
8. Elwell LP, Falkow S. The characterization of R plasmids and the
detection of plasmid-speciﬁed genes. In: Lorian V, ed. Antibiotics in
laboratory medicine, 2nd edn. Baltimore, MD: Williams and Wilkins,
1986; 683–721.
9. Matthew MA, Harris AM, Marshall MJ, Ross GW. The use of isoelectric
focusing for detection and identiﬁcation of b-lactamases. J Gen Microbiol
1975; 88: 169–178.
10. N€uesch-Inderbinen MT, H€achler H, Kayser FH. Detection of genes
coding for extended-spectrum SHV b-lactamases in clinical isolates by a
molecular genetic method, and comparison with the E test. Eur J Clin
Microbiol Infect Dis 1996; 15: 398–402.
11. Arlet G, Brami G, Decre D, Flippo A, Gaillot O, Lagrange PH.
Molecular characterization by PCR restriction fragment polymorphism
of TEM b-lactamases. FEMS Microbiol Lett 1995; 134: 203–208.
12. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital
spread of Escherichia coli producing CTX-M extended-spectrum
b-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735–743.
13. Pagani L, Mantengoli E, Migliavacca R et al. Multifocal detection of
multidrug-resistant Pseudomonas aeruginosa producing PER-1
extended-spectrum b-lactamase in Northern Italy. J Clin Microbiol
2004; 42: 2523–2529.
14. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC
b-lactamase genes in clinical isolates by using multiplex PCR. J Clin
Microbiol 2002; 40: 2153–2162.
15. Poirel L, Walsh TR, Cuveiller V, Nordman P. Multiplex PCR for
detection of acquired carbapenemases genes. Diagn Microbiol Infect Dis
2011; 70: 119–125.
16. Jeong SK, Lee K, Chong Y et al. Characterization of a new integron
containing VIM-2, a metallo-b-lactamase gene cassette, in a clinical
isolate of Enterobacter cloacae. J Antimicrob Chemother 2003; 51: 397–
400.
17. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of
plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6:
629–640.
18. Miro E, Segura C, Navarro F et al. Spread of plasmids containing the
blaVIM-1 and blaCTX-M genes and the qnr determinants in Enterobacter
cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates. J Antimicrob
Chemother 2010; 65: 661–665.
O902 Clinical Microbiology and Infection, Volume 20 Number 11, November 2014 CMI
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O894–O903
19. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threfall EJ.
Identiﬁcation of plasmids by PCR-based replicon typing. J Microbiol
Methods 2005; 63: 219–228.
20. Kaufman ME. Pulsed-ﬁeld gel electrophoresis. In: Woodford N,
Johnsons A, eds. Molecular bacteriology. Protocols and clinical applica-
tions, 1st edn. Totowa, NJ: Humana Press, 1998; 33–51.
21. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus
sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin
Microbiol 2005; 43: 4178–4182.
22. Canton R, Akova M, Carmeli Y et al. Rapid evolution and spread of
carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol
Infect 2012; 18: 413–431.
23. Yan JJ, Ko WC, Chuang C, Wu JJ. Metallo b-lactamase-producing
Enterobacteriaceae in a university hospital in Taiwan: preva-
lence of IMP-8 Enterobacter cloacae and ﬁrst identiﬁcation of
VIM-2 in Citrobacter freundii. J Antimicrob Chemother 2002; 50:
503–511.
24. Yong D, Toleman MA, Giske CG et al. Characterization of a new
metallo-b-lactamase gene, blaNDM-1, and a novel erythromycin esterase
gene carried on a unique genetic structure in Klebsiella pneumoniae
sequence type 14 from India. Antimicrob Agents Chemother 2009; 53:
5046–5054.
25. Mulvey MR, Grant JM, Plewes K, Roscoe D, Boyd DA. New Delhi
metallo-b-lactamase in Klebsiella pneumoniae and Escherichia coli,
Canada. Emerg Infect Dis 2011; 17: 103–106.
26. Zarfel G, Hoenigl M, W€urstl B et al. Emergence of carbapenem-resis-
tant Enterobacteriaceae in Austria 2001–2010. Clin Microbiol Infect 2011;
17: E5–E8.
27. Chu YW, Tung VWN, Cheung TKM et al. Carbapenemases in Entero-
bacteriaceae, HongKong, China 2009. Emerg Infect Dis 2011; 17: 130–132.
28. Tsang Ky, Luk S, Lo JC, Tsang TY, Lai ST, Ng TK. Hong-Kong
experiences the ‘ultimate superbag’ NDM-1 Enterobacteriaceae. Hong
Kong Med J 2012; 18: 439–441.
29. Casthanheira M, Desphande LM, Mathai D, Bell JM, Jones RN, Mendes
E. Early dissemination of NDM-1 and OXA-181 producing Enterobac-
teriaceae in Indian hospitals: report from the SENTRY Antimicrobial
Surveillance Program, 2006–2007. Antimicrob Agents Chemother 2011;
55: 1274–1278.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O894–O903
CMI Research Note O903
